

PB 88 of 2020

National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020

National Health Act 1953

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the *National Health Act 1953*.

Dated: 9 September 2020

THEA CONNOLLY

Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health

1 Name of Instrument

- (1) This instrument is the National Health (Weighted average disclosed price October 2020 reduction day) Amendment Determination 2020.
- (2) This instrument may also be cited as PB 88 of 2020.

2 Commencement

This instrument commences on the day after it is registered.

3 Amendments to PB 54 of 2020

Schedule 1 amends the *National Health (Weighted average disclosed price – October 2020 reduction day) Determination 2020* (PB 54 of 2020).

² National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020

Schedule 1 Amendments

[1] Schedule 1

after:

77	Entecavir	Tablet 1 mg (as monohydrate)	Oral	ENTECLUDE	117.91

omit:

70	Painshiain	Solution for injection containing epirubicin	T:	Enimalsia ACT	25.40
78	Epirubicin	hydrochloride 100 mg in 50 mL	Injection/intravesical	Epirubicin ACT	25.49
		Solution for injection containing epirubicin			
79	Epirubicin	hydrochloride 200 mg in 100 mL	Injection/intravesical	Epirube	50.98
		Solution for injection containing epirubicin			
80	Epirubicin	hydrochloride 200 mg in 100 mL	Injection/intravesical	Epirubicin Accord	50.98
		Solution for injection containing epirubicin			
81	Epirubicin	hydrochloride 200 mg in 100 mL	Injection/intravesical	Epirubicin ACT	50.98
		Solution for injection containing epirubicin			
82	Epirubicin	hydrochloride 50 mg in 25 mL	Injection/intravesical	Epirube	12.75
		Solution for injection containing epirubicin			
83	Epirubicin	hydrochloride 50 mg in 25 mL	Injection/intravesical	Epirubicin ACT	12.75
84	Etoposide	Powder for I.V. infusion 1 g (as phosphate)	Injection	Etopophos	342.38
85	Etoposide	Solution for I.V. infusion 100 mg in 5 mL	Injection	Etoposide Ebewe	34.24
86	Etoposide	Solution for I.V. infusion 100 mg in 5 mL	Injection	Pfizer Australia Pty Ltd	34.24

[2] Schedule 1

after:

		Solution for I.V. infusion 4 mg (as monohydrate)			
228	Zoledronic acid	in 100 mL	Injection	DBL Zoledronic Acid	72.79

omit:

3

		Solution for I.V. infusion 5 mg (as monohydrate)			
229	Zoledronic acid	in 100 mL	Injection	Aclasta	97.45
		Solution for I.V. infusion 5 mg (as monohydrate)			
230	Zoledronic acid	in 100 mL	Injection	Osteovan	97.45
		Solution for I.V. infusion 5 mg (as monohydrate)			
231	Zoledronic acid	in 100 mL	Injection	Ostira	97.45
		Solution for I.V. infusion 5 mg (as monohydrate)			
232	Zoledronic acid	in 100 mL	Injection	Zoledasta	97.45

substitute:

		Solution for I.V. infusion 5 mg (as monohydrate)			
229	Zoledronic acid	in 100 mL	Injection	Aclasta	97.47
		Solution for I.V. infusion 5 mg (as monohydrate)			
230	Zoledronic acid	in 100 mL	Injection	Osteovan	97.47
		Solution for I.V. infusion 5 mg (as monohydrate)			
231	Zoledronic acid	in 100 mL	Injection	Ostira	97.47
		Solution for I.V. infusion 5 mg (as monohydrate)			
232	Zoledronic acid	in 100 mL	Injection	Zoledasta	97.47

Schedule 2 Amendments

[3] Schedule 2

after:

		Injection containing enoxaparin sodium 80 mg			
1,024	Enoxaparin	(8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe	Injection	Enoxaparin Winthrop	54.37

insert:

4

		Solution for injection containing epirubicin			
1,024A E	Epirubicin	hydrochloride 100 mg in 50 mL	Injection/intravesical	Epirubicin ACT	25.49

		Solution for injection containing epirubicin			
1,024B	Epirubicin	hydrochloride 200 mg in 100 mL	Injection/intravesical	Epirube	50.98
		Solution for injection containing epirubicin			
1,024C	Epirubicin	hydrochloride 200 mg in 100 mL	Injection/intravesical	Epirubicin Accord	50.98
		Solution for injection containing epirubicin			
1,024D	Epirubicin	hydrochloride 200 mg in 100 mL	Injection/intravesical	Epirubicin ACT	50.98
		Solution for injection containing epirubicin			
1,024E	Epirubicin	hydrochloride 50 mg in 25 mL	Injection/intravesical	Epirube	12.75
		Solution for injection containing epirubicin			
1,024F	Epirubicin	hydrochloride 50 mg in 25 mL	Injection/intravesical	Epirubicin ACT	12.75

[4] Schedule 2

after:

1,125	Etoposide	Capsule 50 mg	Oral	Vepesid	391.11
-------	-----------	---------------	------	---------	--------

insert:

1,125A	Etoposide	Powder for I.V. infusion 1 g (as phosphate)	Injection	Etopophos	342.38
1,125B	Etoposide	Solution for I.V. infusion 100 mg in 5 mL	Injection	Etoposide Ebewe	34.24
1,125C	Etoposide	Solution for I.V. infusion 100 mg in 5 mL	Injection	Pfizer Australia Pty Ltd	34.24

[5] Schedule 2

after:

		Tablet containing imipramine hydrochloride 25			
1,594	Imipramine	mg	Oral	Tofranil 25	7.11

insert:

	Tablet containing imipramine hy	ydrochloride 25		
1,594A Imipramine	e mg USP	Oral	Imipramine (Leading)	19.00

[6] Schedule 2

				Carbidopa and Levodopa	
1,902	Levodopa with carbidopa	Tablet 250 mg-25 mg (USP)	Oral	Tablets, USP	44.63
insert:					
	Levodopa with carbidopa				
1,902A	and entacapone	Tablet 100 mg-25 mg (as monohydrate)-200 mg	Oral	Lecteva	110.74
	Levodopa with carbidopa				
1,902B	and entacapone	Tablet 100 mg-25 mg (as monohydrate)-200 mg	Oral	Carlevent	110.74
	Levodopa with carbidopa				
1,902C	and entacapone	Tablet 100 mg-25 mg (as monohydrate)-200 mg	Oral	Stalevo 100/25/200mg	110.74
	Levodopa with carbidopa				
1,902D	and entacapone	Tablet 150 mg-37.5 mg (as monohydrate)-200 mg	Oral	Lecteva	121.22
	Levodopa with carbidopa				
1,902E	and entacapone	Tablet 150 mg-37.5 mg (as monohydrate)-200 mg	Oral	Carlevent	121.22
	Levodopa with carbidopa				
1,902F	and entacapone	Tablet 150 mg-37.5 mg (as monohydrate)-200 mg	Oral	Stalevo 150/37.5/200mg	121.22
	Levodopa with carbidopa				
1,902G	and entacapone	Tablet 50 mg-12.5 mg (as monohydrate)-200 mg	Oral	Carlevent	100.26
	Levodopa with carbidopa				
1,902H	and entacapone	Tablet 50 mg-12.5 mg (as monohydrate)-200 mg	Oral	Lecteva	100.26
	Levodopa with carbidopa				
1,902I	and entacapone	Tablet 50 mg-12.5 mg (as monohydrate)-200 mg	Oral	Stalevo 50/12.5/200mg	100.26
	Levodopa with carbidopa			_	
1,902J	and entacapone	Tablet 125 mg-31.25 mg (as monohydrate)-200 mg	Oral	Lecteva	114.94
	Levodopa with carbidopa				
1,902K	and entacapone	Tablet 125 mg-31.25 mg (as monohydrate)-200 mg	Oral	Stalevo 125/31.25/200mg	114.94
1.000*	Levodopa with carbidopa	T.11 . 105	0 1		11464
1,902L	and entacapone	Tablet 125 mg-31.25 mg (as monohydrate)-200 mg	Oral	Carlevent	114.94
1,902	Levodopa with carbidopa	T.11 . 200	0 1		120.05
M	and entacapone	Tablet 200 mg-50 mg (as monohydrate)-200 mg	Oral	Carlevent	130.86

	Levodopa with carbidopa				
1,902N	and entacapone	Tablet 200 mg-50 mg (as monohydrate)-200 mg	Oral	Stalevo 200/50/200mg	130.86
	Levodopa with carbidopa				
1,9020	and entacapone	Tablet 200 mg-50 mg (as monohydrate)-200 mg	Oral	Lecteva	130.86
	Levodopa with carbidopa				
1,902P	and entacapone	Tablet 75 mg-18.75 mg (as monohydrate)-200 mg	Oral	Lecteva	104.87
	Levodopa with carbidopa				
1,902Q	and entacapone	Tablet 75 mg-18.75 mg (as monohydrate)-200 mg	Oral	Carlevent	104.87
	Levodopa with carbidopa				
1,902R	and entacapone	Tablet 75 mg-18.75 mg (as monohydrate)-200 mg	Oral	Stalevo 75/18.75/200mg	104.87

[7] Schedule 2

after:

1,954	Losartan	Tablet containing losartan potassium 50 mg	Oral	Cozavan	7.25

insert:

		Tablet containing lurasidone hydrochloride			
1,954A	Lurasidone	40 mg	Oral	Lurasidone Lupin	46.48
		Tablet containing lurasidone hydrochloride			
1,954B	Lurasidone	40 mg	Oral	Ardix Lurasidone	46.48
		Tablet containing lurasidone hydrochloride			
1,954C	Lurasidone	40 mg	Oral	Latuda	46.48
		Tablet containing lurasidone hydrochloride			
1,954D	Lurasidone	80 mg	Oral	Latuda	92.96
		Tablet containing lurasidone hydrochloride			
1,954E	Lurasidone	80 mg	Oral	Ardix Lurasidone	92.96
		Tablet containing lurasidone hydrochloride			
1,954F	Lurasidone	80 mg	Oral	Lurasidone Lupin	92.96

[8] Schedule 2

National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020

2,035	Metformin	Tablet (extended release) containing metformin hydrochloride 500 mg	Oral	Metformin XR 500 APOTEX	3.72
insert:					
2.035A	Metformin	Tablet (prolonged release) containing metformin hydrochloride 500 mg	Oral	Metformin (Medsurge)	4.01

[9] Schedule 2

after:

2,096	Methylphenidate	Capsule containing methylphenidate hydrochloride 40 mg (modified release)	Oral	Ritalin LA	38.07
insert:					
		Capsule containing methylphenidate			
2,096A	Methylphenidate	hydrochloride 60 mg (modified release)	Oral	Ritalin LA	51.01

[10] Schedule 2

2,367	Nitrazepam	Tablet 5 mg	Oral	Mogadon	1.48
insert:					
2,367A	Nitrofurantoin	Capsule 100 mg	Oral	APO-Nitrofurantoin	14.67
2,367B	Nitrofurantoin	Capsule 100 mg	Oral	Macrodantin	14.67
2,367C	Nitrofurantoin	Capsule 50 mg	Oral	Macrodantin	10.46
2,367D	Nitrofurantoin	Capsule 50 mg	Oral	APO-Nitrofurantoin	10.46

[11] Schedule 2

		Pressurised inhalation 100 micrograms (as sulfate)	Inhalation by		
3,224	Salbutamol	per dose, 200 doses (CFC-free formulation)	mouth	Ventolin CFC-free	3.88
insert:					
		Pressurised inhalation 100 micrograms (as sulfate)			
		per dose with dose counter, 200 doses (CFC-free	Inhalation by	Zempreon CFC-Free with	
3,224A	Salbutamol	formulation)	Mouth	dose counter	4.49
		Pressurised inhalation 100 micrograms (as sulfate)			
		per dose with dose counter, 200 doses (CFC-free	Inhalation by	Ventolin CFC-Free with	
3,224B	Salbutamol	formulation)	Mouth	dose counter	4.49